Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of "Buy" by Analysts

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) has been assigned a consensus rating of "Buy" from the seven analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $63.67.

A number of brokerages have commented on TARS. Barclays lowered their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Oppenheimer raised their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a report on Wednesday, January 22nd. Jefferies Financial Group upped their price objective on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. Guggenheim restated a "buy" rating and set a $78.00 target price (up from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday, February 24th. Finally, HC Wainwright reiterated a "buy" rating and set a $73.00 price target on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th.

Tarsus Pharmaceuticals Stock Down 2.7 %

NASDAQ:TARS traded down $1.37 on Monday, hitting $48.93. 229,986 shares of the company's stock traded hands, compared to its average volume of 692,643. The firm has a 50-day moving average price of $47.82 and a 200-day moving average price of $48.67. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The company has a market cap of $1.88 billion, a PE ratio of -12.97 and a beta of 0.94. Tarsus Pharmaceuticals has a 1 year low of $20.08 and a 1 year high of $57.28.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The company had revenue of $78.34 million during the quarter, compared to the consensus estimate of $72.50 million. Equities analysts anticipate that Tarsus Pharmaceuticals will post -3.17 EPS for the current fiscal year.

Insider Transactions at Tarsus Pharmaceuticals

In other news, General Counsel Bryan Wahl sold 3,341 shares of the company's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total transaction of $154,654.89. Following the completion of the transaction, the general counsel now owns 58,057 shares of the company's stock, valued at approximately $2,687,458.53. This represents a 5.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bobak R. Azamian sold 6,000 shares of the business's stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $50.00, for a total value of $300,000.00. Following the transaction, the chief executive officer now owns 824,106 shares in the company, valued at $41,205,300. This represents a 0.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,542 shares of company stock worth $1,581,173 over the last three months. 8.25% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Toronto Dominion Bank acquired a new stake in Tarsus Pharmaceuticals in the 4th quarter valued at $105,714,000. Lord Abbett & CO. LLC lifted its holdings in shares of Tarsus Pharmaceuticals by 115.2% during the fourth quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company's stock valued at $70,873,000 after acquiring an additional 685,111 shares during the period. Millennium Management LLC boosted its stake in shares of Tarsus Pharmaceuticals by 189.4% in the 4th quarter. Millennium Management LLC now owns 644,010 shares of the company's stock valued at $35,659,000 after purchasing an additional 421,495 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Tarsus Pharmaceuticals by 2,088.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company's stock worth $14,477,000 after purchasing an additional 420,057 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC lifted its holdings in Tarsus Pharmaceuticals by 5,636.3% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 404,237 shares of the company's stock valued at $22,383,000 after purchasing an additional 397,190 shares during the last quarter. Institutional investors own 90.01% of the company's stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.